PL3787596T3 - Ulepszone formulacje farmaceutyczne - Google Patents
Ulepszone formulacje farmaceutyczneInfo
- Publication number
- PL3787596T3 PL3787596T3 PL19719868.2T PL19719868T PL3787596T3 PL 3787596 T3 PL3787596 T3 PL 3787596T3 PL 19719868 T PL19719868 T PL 19719868T PL 3787596 T3 PL3787596 T3 PL 3787596T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical formulations
- improved pharmaceutical
- improved
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201811016594 | 2018-05-02 | ||
| PCT/EP2019/060605 WO2019211159A1 (en) | 2018-05-02 | 2019-04-25 | Improved pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3787596T3 true PL3787596T3 (pl) | 2025-11-12 |
Family
ID=66290450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19719868.2T PL3787596T3 (pl) | 2018-05-02 | 2019-04-25 | Ulepszone formulacje farmaceutyczne |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11648201B2 (pl) |
| EP (2) | EP3787596B1 (pl) |
| JP (1) | JP7516259B2 (pl) |
| KR (1) | KR20210005224A (pl) |
| CN (1) | CN112040929B (pl) |
| BR (1) | BR112020021852A2 (pl) |
| CA (1) | CA3099055A1 (pl) |
| CL (1) | CL2020002766A1 (pl) |
| CO (1) | CO2020013679A2 (pl) |
| ES (1) | ES3041575T3 (pl) |
| FI (1) | FI3787596T3 (pl) |
| MX (2) | MX2020011541A (pl) |
| PH (1) | PH12020551798A1 (pl) |
| PL (1) | PL3787596T3 (pl) |
| SG (1) | SG11202010792TA (pl) |
| TW (1) | TW202002953A (pl) |
| WO (1) | WO2019211159A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146164B1 (en) * | 2020-05-08 | 2025-04-30 | Fertin Pharma A/S | Flowpack for oral delivery of active ingredients |
| TW202430129A (zh) * | 2023-01-17 | 2024-08-01 | 荷蘭商菲林公司 | 改進的西地那非藥物配製物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2716624B1 (fr) * | 1994-02-25 | 1996-05-03 | Jouveinal Lab | Gelée laxative hypocalorique à base d'huile de paraffine liquide et de lactulose, son procédé de préparation. |
| ITFI970184A1 (it) | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico |
| RU2175554C2 (ru) | 1999-03-30 | 2001-11-10 | Пермское научно-производственное объединение "Биомед" | Оральный препарат интерферона в виде таблеток |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EP1235561A2 (en) * | 1999-11-30 | 2002-09-04 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
| WO2006020534A2 (en) | 2004-08-09 | 2006-02-23 | Dr. Reddy's Laboratories Ltd. | Stabilized desloratadine composition |
| DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| CN101180038A (zh) * | 2005-03-23 | 2008-05-14 | 伊兰制药国际有限公司 | 纳米颗粒皮质类固醇和抗组胺药制剂 |
| US20090004270A1 (en) | 2006-01-06 | 2009-01-01 | Amerilab Technologies, Inc. | Method of using guava extract |
| US7611739B2 (en) * | 2006-01-06 | 2009-11-03 | Amerilab Technologies, Inc. | Method of using guava extract and composition including guava extract |
| EP1970053A1 (en) | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| EP2240174A1 (en) * | 2008-02-13 | 2010-10-20 | Ratiopharm GmbH | Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide |
| WO2009112156A1 (en) | 2008-03-10 | 2009-09-17 | Bayer Consumer Care Ag | Palatable solid composition comprising antacid and saliva stimulant |
| EP2262536A4 (en) * | 2008-03-26 | 2013-07-03 | Taro Pharmaceuticals North America Inc | STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS |
| TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| RU2454221C2 (ru) | 2010-07-06 | 2012-06-27 | Общество с ограниченной ответственностью "Завод Медсинтез" | Способ получения лиофилизированного противовирусного средства |
| EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| EA201391053A1 (ru) | 2011-01-17 | 2013-12-30 | Такеда Фармасьютикал Компани Лимитед | Таблетка, диспергируемая в ротовой полости |
| WO2013077829A1 (en) | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Water-soluble pharmaceutical granules |
| MX374014B (es) * | 2012-05-16 | 2020-07-24 | Mewa Singh | Composiciones farmaceuticas para la entrega de farmacos insolubles en agua. |
| CA2914583C (en) | 2013-06-04 | 2019-06-18 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
-
2019
- 2019-04-25 EP EP19719868.2A patent/EP3787596B1/en active Active
- 2019-04-25 MX MX2020011541A patent/MX2020011541A/es unknown
- 2019-04-25 SG SG11202010792TA patent/SG11202010792TA/en unknown
- 2019-04-25 WO PCT/EP2019/060605 patent/WO2019211159A1/en not_active Ceased
- 2019-04-25 CA CA3099055A patent/CA3099055A1/en active Pending
- 2019-04-25 KR KR1020207034567A patent/KR20210005224A/ko active Pending
- 2019-04-25 EP EP25184473.4A patent/EP4603095A3/en active Pending
- 2019-04-25 US US17/051,732 patent/US11648201B2/en active Active
- 2019-04-25 ES ES19719868T patent/ES3041575T3/es active Active
- 2019-04-25 CN CN201980028696.XA patent/CN112040929B/zh active Active
- 2019-04-25 BR BR112020021852-9A patent/BR112020021852A2/pt unknown
- 2019-04-25 PL PL19719868.2T patent/PL3787596T3/pl unknown
- 2019-04-25 JP JP2020561663A patent/JP7516259B2/ja active Active
- 2019-04-25 FI FIEP19719868.2T patent/FI3787596T3/fi active
- 2019-04-30 TW TW108115070A patent/TW202002953A/zh unknown
-
2020
- 2020-10-26 CL CL2020002766A patent/CL2020002766A1/es unknown
- 2020-10-28 PH PH12020551798A patent/PH12020551798A1/en unknown
- 2020-10-29 MX MX2023008569A patent/MX2023008569A/es unknown
- 2020-10-30 CO CONC2020/0013679A patent/CO2020013679A2/es unknown
-
2023
- 2023-03-30 US US18/128,922 patent/US12016955B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3787596A1 (en) | 2021-03-10 |
| CN112040929B (zh) | 2024-08-30 |
| WO2019211159A1 (en) | 2019-11-07 |
| CN112040929A (zh) | 2020-12-04 |
| US20230346704A1 (en) | 2023-11-02 |
| CO2020013679A2 (es) | 2021-03-19 |
| EP4603095A3 (en) | 2025-11-19 |
| ES3041575T3 (en) | 2025-11-13 |
| FI3787596T3 (fi) | 2025-09-29 |
| MX2020011541A (es) | 2020-11-24 |
| CL2020002766A1 (es) | 2021-02-19 |
| US20210236426A1 (en) | 2021-08-05 |
| MX2023008569A (es) | 2023-08-08 |
| BR112020021852A2 (pt) | 2021-02-23 |
| EP4603095A2 (en) | 2025-08-20 |
| EP3787596B1 (en) | 2025-06-25 |
| PH12020551798A1 (en) | 2021-06-14 |
| JP7516259B2 (ja) | 2024-07-16 |
| CA3099055A1 (en) | 2019-11-07 |
| US12016955B2 (en) | 2024-06-25 |
| KR20210005224A (ko) | 2021-01-13 |
| SG11202010792TA (en) | 2020-11-27 |
| TW202002953A (zh) | 2020-01-16 |
| US11648201B2 (en) | 2023-05-16 |
| JP2021522299A (ja) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| PT4070788T (pt) | Formulações farmacêuticas | |
| EP3641771A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| DK3655017T3 (da) | Farmaceutisk sammensætning | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| IL285674A (en) | Pharmaceutical formulations | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| DK3886820T3 (da) | Kapselformuleringer | |
| IL283900A (en) | Pharmaceutical combinations | |
| EP3785698A4 (en) | Edaravone pharmaceutical composition | |
| EP3454847A4 (en) | IMPROVED DRUG FORMULATIONS | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| DK3709970T3 (da) | Linezolidformuleringer | |
| HUE063178T2 (hu) | Kopanlizib formulációi | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3646866A4 (en) | PHARMACEUTICAL PREPARATION | |
| HUE069648T2 (hu) | Gyógyszerészeti készítmény | |
| EP4013441A4 (en) | LARAZOTIDE FORMULATIONS | |
| DK3911298T3 (da) | Formuleringer | |
| IL272167A (en) | Hemopexin formulations | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| EP3746080A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3601277T3 (da) | Farmaceutisk formulering |